Market research
ZOE.F Zoetis Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 29B
- P/E ratio
- 13.66
- Analyst target
- 224.58
- Dividend yield
- 2.9%
- Beta
- 0.74
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 29B
- P/E ratio
- 13.66
- Analyst target
- 224.58
- Dividend yield
- 2.9%
- Beta
- 0.74
About
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZOE.F discussion.
5 years, 6 months ago
Zoetis Inc is currently in a long term uptrend where the price is trading 20.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.2.
Zoetis Inc's total revenue rose by 7.9% to $2B since the same quarter in the previous year.
Its net income has dropped by 6.5% to $359M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.1% to $566M since the same quarter in the previous year.
Based on the above factors, Zoetis Inc gets an overall score of 4/5.